Apogee Therapeutics (APGE) Non-Current Assets (2023 - 2026)
Apogee Therapeutics (APGE) reported Non-Current Assets of $219.9 million for Q1 2026, up 14.13% year-over-year from $192.6 million in Q1 2025, and up 12.3% on a QoQ basis from $195.8 million in Q4 2025.
Apogee Therapeutics (APGE) has 4 years of Non-Current Assets data on file, last reported at $219.9 million in Q1 2026.
- Quarterly Non-Current Assets rose 14.13% year-over-year to $219.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $643.3 million (down 17.25% YoY) and the FY2025 annual result came in at $195.8 million, down 12.69% from the prior year.
- Non-Current Assets advanced to $219.9 million in Q1 2026 per APGE's latest filing, from $195.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $241.8 million in Q3 2024 and bottomed at $3.0 million in Q4 2023.
- The 4-year median for Non-Current Assets is $167.1 million (2025), against an average of $142.7 million.
- The widest annual swing landed in 2024, when Non-Current Assets soared 7387.08%; it then slumped 64.41% in 2025.
- Tracing APGE's Non-Current Assets over 4 years: stood at $3.0 million in 2023, then soared by 7387.08% to $224.2 million in 2024, then decreased by 12.69% to $195.8 million in 2025, then advanced by 12.3% to $219.9 million in 2026.
- Per Business Quant, the three latest APGE Non-Current Assets figures stand at $219.9 million (Q1 2026), $195.8 million (Q4 2025), and $86.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | 219.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 219.86 Mn |
| Dec 31, 2025 | 195.78 Mn |
| Sep 30, 2025 | 86.06 Mn |
| Jun 30, 2025 | 141.65 Mn |
| Mar 31, 2025 | 192.63 Mn |
| Dec 31, 2024 | 224.24 Mn |
| Sep 30, 2024 | 241.80 Mn |
| Jun 30, 2024 | 118.80 Mn |
| Mar 31, 2024 | 3.05 Mn |
| Dec 31, 2023 | 3.00 Mn |